124 related articles for article (PubMed ID: 36149168)
41. Comparison between DVH-based doses and ICRU point-based doses to the rectum and the bladder using CT-based high-dose rate brachytherapy to the cervix.
Rangarajan R; Subramanian S; Gopalakrishnan K
Med Dosim; 2018 Autumn; 43(3):276-283. PubMed ID: 29198390
[TBL] [Abstract][Full Text] [Related]
42. Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy.
Huckle A; Al-Qaisieh B; Bownes P
Radiother Oncol; 2012 May; 103(2):261-5. PubMed ID: 22098792
[TBL] [Abstract][Full Text] [Related]
43. A comparison between tandem and ovoids and interstitial gynecologic template brachytherapy dosimetry using a hypothetical computer model.
Hsu IC; Speight J; Hai J; Vigneault E; Phillips T; Pouliot J
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):538-43. PubMed ID: 11872302
[TBL] [Abstract][Full Text] [Related]
44. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
Cheng JC; Peng LC; Chen YH; Huang DY; Wu JK; Jian JJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1010-8. PubMed ID: 14575832
[TBL] [Abstract][Full Text] [Related]
45. The dosimetric impact of heterogeneity corrections in high-dose-rate ¹⁹²Ir brachytherapy for cervical cancer: Investigation of both conventional Point-A and volume-optimized plans.
Hyer DE; Sheybani A; Jacobson GM; Kim Y
Brachytherapy; 2012; 11(6):515-20. PubMed ID: 22386723
[TBL] [Abstract][Full Text] [Related]
46. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy.
Levitchi M; Charra-Brunaud C; Quetin P; Haie-Meder C; Kerr C; Castelain B; Delannes M; Thomas L; Desandes E; Peiffert D
Radiother Oncol; 2012 Jun; 103(3):314-21. PubMed ID: 22633813
[TBL] [Abstract][Full Text] [Related]
47. Using the computed tomography in comparison to the orthogonal radiography based treatment planning in high dose rate (HDR) brachytherapy in cervical uteri cancer patients; a single institution feasibility study.
Bahadur YA; El-Sayed ME; El-Taher ZH; Zaza KO; Moftah BA; Hassouna AH; Ghassal NM
J Egypt Natl Canc Inst; 2008 Mar; 20(1):1-9. PubMed ID: 19847276
[TBL] [Abstract][Full Text] [Related]
48. A novel two-step optimization method for tandem and ovoid high-dose-rate brachytherapy treatment for locally advanced cervical cancer.
Sharma M; Fields EC; Todor DA
Brachytherapy; 2015; 14(5):613-8. PubMed ID: 26092424
[TBL] [Abstract][Full Text] [Related]
49. Comparison of DVH parameters and loading patterns of standard loading, manual and inverse optimization for intracavitary brachytherapy on a subset of tandem/ovoid cases.
Jamema SV; Kirisits C; Mahantshetty U; Trnkova P; Deshpande DD; Shrivastava SK; Pötter R
Radiother Oncol; 2010 Dec; 97(3):501-6. PubMed ID: 20846734
[TBL] [Abstract][Full Text] [Related]
50. 3D CT-based volumetric dose assessment of 2D plans using GEC-ESTRO guidelines for cervical cancer brachytherapy.
Gao M; Albuquerque K; Chi A; Rusu I
Brachytherapy; 2010; 9(1):55-60. PubMed ID: 19853536
[TBL] [Abstract][Full Text] [Related]
51. Interfraction physical dose variations in high-dose-rate brachytherapy for carcinoma cervix based on computed tomography image dataset to find the compatibility of the first fraction plan to treat successive fractions.
Yadav S; Singh OP; Choudhary S; Saroj DK; Maurya AK; Yogi V
J Cancer Res Ther; 2019; 15(6):1304-1308. PubMed ID: 31898664
[TBL] [Abstract][Full Text] [Related]
52. Conformal brachytherapy planning for cervical cancer using transabdominal ultrasound.
Van Dyk S; Narayan K; Fisher R; Bernshaw D
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):64-70. PubMed ID: 19250767
[TBL] [Abstract][Full Text] [Related]
53. Effect of different definitions of prescription point "A" in high dose rate brachytherapy for cervical cancer.
Srivastava S; Painuly NK; Mishra SP; Srivastava K; Singh N; Bhatt MLB
J Cancer Res Ther; 2019; 15(6):1365-1369. PubMed ID: 31898674
[TBL] [Abstract][Full Text] [Related]
54. A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes.
Siavashpour Z; Aghamiri MR; Jaberi R; ZareAkha N; Manshadi HRD; Kirisits C; Sedaghat M
J Appl Clin Med Phys; 2016 May; 17(3):5-13. PubMed ID: 27167253
[TBL] [Abstract][Full Text] [Related]
55. Problems in reporting doses and volumes during multiple high-dose-rate intracavitary brachytherapy for carcinoma cervix as per ICRU Report 38: a comparative study using flexible and rigid applicators.
Datta NR; Basu R; Das KJ; Rajasekar D; Pandey CM; Ayyagari S
Gynecol Oncol; 2003 Nov; 91(2):285-92. PubMed ID: 14599857
[TBL] [Abstract][Full Text] [Related]
56. Additional rectal and sigmoid mucosal points and doses in high dose rate intracavitary brachytherapy for carcinoma cervix: a dosimetric study.
Mahantshetty U; Tiwana MS; Jamema S; Mishra S; Engineer R; Deshpande D; Shrivastava S
J Cancer Res Ther; 2011; 7(3):298-303. PubMed ID: 22044811
[TBL] [Abstract][Full Text] [Related]
57. Comparison of dose-volume analysis between standard Manchester plan and magnetic resonance image-based plan of intracavitary brachytherapy for uterine cervical cancer.
Takenaka T; Yoshida K; Tachiiri S; Yamazaki H; Aramoto K; Furuya S; Yoshida M; Ban C; Tanaka E; Honda K
J Radiat Res; 2012 Sep; 53(5):791-7. PubMed ID: 22843369
[TBL] [Abstract][Full Text] [Related]
58. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
[TBL] [Abstract][Full Text] [Related]
59. Image-guided cervix high-dose-rate brachytherapy treatment planning: does custom computed tomography planning for each insertion provide better conformal avoidance of organs at risk?
Davidson MT; Yuen J; D'Souza DP; Batchelar DL
Brachytherapy; 2008; 7(1):37-42. PubMed ID: 18299111
[TBL] [Abstract][Full Text] [Related]
60. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
Beriwal S; Kim H; Heron DE; Selvaraj R
Technol Cancer Res Treat; 2006 Oct; 5(5):521-7. PubMed ID: 16981795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
